Consensus AstraZeneca PLC

Equities

Market Closed - London S.E. Other stock markets 11:35:11 2025-01-23 am EST			5-day change	1st Jan Change
11,046.00 ^GBX	+0.05%		+1.86%	+5.52%

Jan. 23	AstraZeneca makes USD570 million investment in Canada in pipeline push	AN
Jan. 23	Astrazeneca to Invest $570 Million in Canadian Operations	MT

da9.AicgZD-BpqI5nb62gjY6LGmAntPEZ7LSXyC28f2yfF8.NGZiXVTP7tVD6tv9yFcPez2xq-X2XuigLU3CvpDDHRVVdHMzTsPewUjY1Q~fceac42d00d9ae167a3f9148b66bf0d2

ASTRAZENECA : Goldman Sachs gives a Buy rating	Jan. 21	ZD
ASTRAZENECA : Gets a Neutral rating from Jefferies	Jan. 20	ZD
ASTRAZENECA : JP Morgan reaffirms its Buy rating	Jan. 15	ZD
Two experts give tips on dividend portfolios	Jan. 14	FW
ASTRAZENECA : Goldman Sachs reiterates its Buy rating	Jan. 13	ZD
Handelsbanken makes several changes to its sector favorites	Jan. 13	FW
Di adds Sampo to low-risk portfolio, SCA removed	Jan. 09	FW
ASTRAZENECA : Buy rating from Berenberg	Jan. 07	ZD
ASTRAZENECA : Bernstein reiterates its Buy rating	Jan. 07	ZD
ASTRAZENECA : JP Morgan maintains a Buy rating	Jan. 06	ZD
ASTRAZENECA : Gets a Neutral rating from Deutsche Bank	Dec. 17	ZD
ASTRAZENECA : Deutsche Bank remains Neutral	Dec. 16	ZD
ASTRAZENECA : Jefferies remains Neutral	Dec. 10	ZD
ASTRAZENECA : Baking in some caution due to the ongoing challenges in China	Dec. 09
ASTRAZENECA : JP Morgan reaffirms its Buy rating	Dec. 09	ZD
ASTRAZENECA : Goldman Sachs gives a Buy rating	Dec. 05	ZD
ASTRAZENECA : JP Morgan reiterates its Buy rating	Dec. 03	ZD
ASTRAZENECA : Goldman Sachs reaffirms its Buy rating	Nov. 25	ZD
Di adds AAK to dividend portfolio, Atrium Ljungberg removed	Nov. 21	FW
Berenberg Trims Price Target on AstraZeneca to GBP140 From GBP150, Keeps Buy Rating	Nov. 20	MT
UBS Upgrades AstraZeneca to Neutral	Nov. 20	MT
ASTRAZENECA : Berenberg cuts its target, but remains Buy	Nov. 20	CF
ASTRAZENECA : UBS is no longer a seller	Nov. 20	CF
ASTRAZENECA : Receives a Buy rating from Berenberg	Nov. 20	ZD
ASTRAZENECA : UBS Upgrades to Neutral	Nov. 20	ZD

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analyst Opinion	4m Revision of opinion	Divergence of analysts' opinions	Divergence of Target Price	Ecart obj. / dr
	ASTRAZENECA PLC					+26.55%
	ELI LILLY AND COMPANY					+29.76%
	NOVO NORDISK A/S					+42.83%
	JOHNSON & JOHNSON					+17.01%
	ABBVIE INC.					+18.19%
	ROCHE HOLDING AG					+10.56%
	MERCK & CO., INC.					+30.78%
	NOVARTIS AG					+14.12%
	PFIZER, INC.					+19.86%
	AMGEN INC.					+16.02%
	Average					+22.57%
	Weighted average by Cap.					+24.58%

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

136.30USD

Average target price

172.34USD

Spread / Average Target

+26.44%

High Price Target

224.81USD

Spread / Highest target

+64.94%

Low Price Target

128.46USD

Spread / Lowest Target

-5.75%

GOLDMAN SACHS	Rajan Sharma
JEFFERIES	Peter Welford
JPMORGAN	James Gordon
BERENBERG	Luisa Hector
BERNSTEIN RESEARCH	Florent Cespedes
alphavalue	Abhishek Raval
UBS
Berenberg Bank
Intron Health
DZ BANK	Elmar Kraus
DEUTSCHE BANK RESEARCH	Emmanuel Papadakis
AlphaValue/Baader Europe
Deutsche Bank Securities
Nordea Bank
BARCLAYS	Emily Field
HSBC
Stifel Nicolaus
Jefferies & Co.
Bernstein
RBC Capital Markets
B. Riley
BMO Capital
CREDIT SUISSE	Dominic Lunn
Argus
Morgan Stanley
Bank of America Securities/Merrill Lynch
Danske Bank Group
Kepler Capital Markets
Kepler Cheuvreux
DEUTSCHE BANK	Emmanuel Papadakis
SVB Leerink
Bryan, Garnier & Co.
Societe Generale
Liberum Capital
ODDO BHF
BANK OF AMERICA (BOFA)	Sachin Jain